IMMUNOPRION is a project at the cutting-edge
of current scientific knowledge on Transmissible
Spongiform Encephalopathies (TSEs). The
project is built around three key issues: the
strain diversity of TSE agents; the crossing of
the species barrier; and the evaluation of the
host innate and acquired immune responses.
TSEs are diseases that affect the brain and
the nervous system of humans and animals,
among which we find what is commonly termed
Mad Cow Disease and its human equivalent,
Creutzfeldt-Jakob disease (vCJD). TSEs are
propagated by prions (a type of infectious
agent made exclusively of protein) through the
food chain.
IMMUNOPRION is investigating the fundamental
features of TSEs to develop the detection of prion
strains for diagnostic procedures and for the
control of their dissemination through the food
chain. The project's objectives are organised
around the idea that a rational food safety
strategy must prevent, predict and protect.
The passage of TSE agents, scrapie form of
the prion (PrPSc), from one species to another
is limited by a so-called species barrier. When
it occurs, this cross-species passage presents
the risk for introducing new prions into the
human food chain.
The strength of this barrier varies considerably
according to the mammalian species: in some
combinations, the passage is almost inexistent,
or requires more infectious material and longer
incubation periods than within members of a
same species. Under natural conditions too,
the species barrier is highly variable: no
evidence of human contamination by ovine
scrapie has been reported so far whereas
hundreds cases of the human new variant vCJD
have been attributed to the bovine spongiform
encephalopathy (BSE) agent.
An important parameter in cross-species
infection resides in the degree of molecular
homology between the infectious PrPSc and
the host prion protein (PrPC). Cell-free systems
confirmed the importance of molecular matching
for efficient conversion of PrPC into PrPSc. Yet,
such in vitro systems parallel only partially the in
vivo reality, suggesting that molecular matching
is not the unique parameter involved and that
additional factors might control the species
barrier effect. One of those factors could be the
host immune system which is known to react
vigorously against xenogeneic PrP and which,
in doing so, could reduce the pathogenicity of
foreign TSE agents.
Aim and expected results:
The diversity of strains
The strain properties of TSE agents are thought
to be enciphered in the structural conformation
of the pathogenic form of PrPSc. The project
will provide a better definition of prion strains
based on their structural and biochemical
properties, and will establish relations with
their physiological and pathological features.
IMMUNOPRION began by producing in vitro
synthetic variants of prions because they
constitute a reliable and homogenous source,
mimicking natural strain diversity. Then, the
project will switch to naturally infectious strains
in mice, hamsters and sheep. A new imaging
technique was set up to identify structures
of prion strains, by means of electron cryotomography
reaching a four-nanometres
resolution, which is not achievable with other
methods. Macromolecular prion assemblies
will then be analysed in gut follicular dendritic
cells (FDCs), which are infected following oral
contamination with different prion strains.
The prion contagion
IMMUNOPRION aims to acquire a better
understanding of the species barrier by
carrying out research using rodents, to probe
the transmission of TSE agents of animal origin to humans. The tropism of human prions is
studied in vivo by means of a dedicated mouse
model combining transgenic expressions of
PrpC from various origins and the graft of a
human immune system. This model allows
direct testing on prions of concern, including
BSE, CWD (Chronic Wasting Disease, in deer)
and other emerging prions strains.
Several lines of evidence support that the
immune system plays a key role during the
stages of the disease. The project aims to
understand how innate immunity, including
dendritic cells and complement, mediates
interactions with specific strains of prions.
There are good reasons to believe that the
host immune system is tolerant to all (or most)
epitopes except those that are buried in PrPC
and are revealed only in transconformed
PrPSc. On the basis of PrPsc structure models,
peptides buried inside the native PrpC are used
in dedicated immunisation protocols to test
for their ability to raise antibody responses in
mouse models.
Potential applications:
A rational food safety policy cannot be attained
without a detailed scientific knowledge of
TSE pathogenesis. This is the reason for the
importance of mouse models in many of the
research activities. The project emphasises
immunological parameters since it appears
that the immune system is an accomplice of the
TSE agent during lympho-invasion. However, it
seems that it may also act as a highly sensitive
alarm and first line of defence.
The potential development of an acquired
immune response against uncovered epitopes
of PrPSc may serve as a witness of infection
and a tool for early diagnosis. Access to the
structural features of various sources of prions
will allow for determining the exact cartography
of the major strains of prions, and will result
in a well-standardised map of prion diversity, which will be used to relate the morphological
specificities to the pathogenic profile. This will
help European countries to define the highest
possible standards of consumer protection,
through better safety of food products.
Therefore, the results of this research will have
a major impact on the development of improved
food safety measures.
Coordinator:
Patrice Marche
Institut Albert Bonniot
Centre de Recherche INSERM-UJF U823
Equipe Immunologie Analytique des
Pathologies Chroniques
UJF Site Santé, BP 170
38042 Grenoble, France
patrice.marche@ujf-grenoble.fr
Partners:
Claude Carnaud, Pierre Aucouturier
Institut National de la Santé et de la
Recherche Médicale
INSERM Unité 712, Hopital Saint-Antoine
Paris, France
Claude.Carnaud@st-antoine.inserm.fr
Pierre.Aucouturier@st-antoine.inserm.fr
Jean-Pierre Liautard
INSERM Unité 431- Université Montpellier II
Montpellier, France
liautard@crit.univ-montp2.fr
Robert Sim
The Chancellor, Masters and Scholars of
the University of Oxford
Department of Biochemistry
MRC Immunochemistry Unit
Oxford, UK
rbsim@bioch.ox.ac.uk
Gordon MacPherson
Sir William Dunn School of Pathology
Oxford, UK
gordon.macpherson@pathology.oxford.ac.uk
Adriano Aguzzi,
Mathias Heikenwaelder
University of Zurich
Institute of Neuropathology
Zurich, Switzerland
mathias.heikenwaelder@usz.ch
Peter Peters
Het Nederlands Kanker Institut
Division Tumor Biology
Amsterdam, Netherlands
ppeters@nki.nl
Christophe Lecante
TecKnowMetrix S.A.R.L.
Voiron, France
cl@tkm.fr
Philippe Derreumaux
Centre National de la Recherche
Scientifique (France)
UPR 9080
Paris, France
Philippe.Derreumaux@ibpc.fr
Ernst Heinen
Universit de Liège
Institute of Human Histology
Liège, Belgium
eheinen@ulg.ac.be
Philippe Arhets
Institut National de la Santé et de la
Recherche Médicale
Paris, France
philippe.arhets@inserm.fr
Pierre Espinasse
The Chancellor, Masters and Scholars of
the University of Oxford
Oxford, UK
Pierre.Espinasse@admin.ox.ac.uk